Bianca Heemskerk

TL;DR: Cancer exome–guided analysis of T-cell reactivity in this patient revealed reactivity against two neoantigens, including a dominant T- cell response against a mutant epitope of the ATR (ataxia telangiectasia and Rad3 related) gene product that increased strongly after ipilimumab treatment.

TL;DR: In both the NL and UK cohorts, long-term benefit of ipilimumab treatment was unlikely for patients with baseline serum LDH greater than twice the upper limit of normal, and baseline serum lactate dehydrogenase was demonstrated to be the strongest predictive factor for OS.

TL;DR: How recent developments in cancer genomics will make it feasible to establish the repertoire of tumour‐associated epitopes on a patient‐specific basis and the elucidation of this ‘cancer antigenome’ will be valuable to reveal how clinically successful immunotherapies mediate their effect are described are described.

TL;DR: Improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells, and have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy.

TL;DR: The ability to identify tumor-reactive TCRs within intratumoral T cell subsets without knowledge of antigen specificities is demonstrated, which may be the first step toward the development of autologous TCR gene therapy to target patient-specific neoantigens in human cancer.